Anticoagulation in Severe Peripheral Artery Disease

Introduction to Anticoagulation Strategies

The European Society of Cardiology recommends combination therapy with low-dose rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily for patients with severe peripheral artery disease (PAD) at high ischemic risk and without high bleeding risk to reduce major adverse cardiovascular events (MACE) and major adverse limb events (MALE) 1, 2

High ischemic risk features in PAD patients include previous amputation, chronic limb-threatening ischemia (CLTI), previous revascularization, heart failure, diabetes mellitus, vascular disease in two or more vascular beds, and moderate kidney dysfunction (eGFR <60 mL/min/1.73 m²) 1
High bleeding risk contraindications to dual pathway inhibition include history of hemorrhagic or lacunar stroke, severe kidney disease, and need for dual antiplatelet therapy or full anticoagulation for another indication 2

For severe PAD without high ischemic risk features, single antiplatelet therapy (SAPT) with clopidogrel 75 mg once daily or aspirin 75-160 mg once daily is recommended (Class I, Level A) 1, 2
For severe PAD with high ischemic risk features and non-high bleeding risk, dual pathway inhibition with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily is recommended (Class IIa, Level A) 1, 2
After lower extremity revascularization, immediate post-procedure therapy with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily is recommended (Class I, Level A for rivaroxaban combination) 1, 2

Long-term dual antiplatelet therapy (aspirin + clopidogrel) is not recommended for chronic PAD without recent revascularization (within 6 months) due to increased bleeding risk 1, 3, 4, 5
Full-intensity oral anticoagulation monotherapy should not be used for PAD without another indication (e.g., atrial fibrillation) as it increases bleeding without reducing MACE or MALE 2, 6

Patients should be assessed for clinical and functional status, medication adherence, and limb symptoms at least annually, with reassessment of ischemic and bleeding risk at every follow-up visit 1, 7
Monitoring for bleeding complications, particularly in the first 3 months of dual pathway therapy, is crucial 2

The American College of Cardiology recommends low-dose rivaroxaban 2.5 mg twice daily combined with low-dose aspirin (81-100 mg daily) after endovascular or surgical revascularization for PAD, with a Class I recommendation (strongest level) for reducing major adverse cardiovascular events (MACE) and major adverse limb events (MALE) 8, 9.
The American College of Cardiology and the American Heart Association provide a Class I recommendation for low-dose rivaroxaban 2.5 mg twice daily plus low-dose aspirin after endovascular or surgical revascularization for PAD, representing the first antithrombotic regimen proven to reduce total mortality and cardiovascular mortality in PAD patients 8, 9.

If rivaroxaban is contraindicated or unavailable, the American College of Cardiology recommends dual antiplatelet therapy (DAPT) with clopidogrel 75 mg plus aspirin 81-100 mg daily for at least 1-6 months after endovascular revascularization 8, 9.
The European Society of Cardiology recommends DAPT for at least one month after infrainguinal stent implantation 10, 11.

The American College of Cardiology advises against using full-dose anticoagulation (warfarin or therapeutic-dose DOACs) solely for PAD or stenting, as it increases bleeding risk without reducing MACE or MALE in PAD patients unless there is another indication such as atrial fibrillation 11.
Long-term DAPT beyond 6 months is not recommended for chronic PAD without recent revascularization due to increased bleeding risk without proven benefit 8.

If the patient requires full-intensity anticoagulation for another indication (e.g., atrial fibrillation with CHA₂DS₂-VASc ≥2), adding single antiplatelet therapy is reasonable if bleeding risk is not high, according to the American College of Cardiology 8, 11.

The European Society of Cardiology recommends monitoring patients for bleeding complications, particularly in the first 3 months of dual pathway therapy, and assessing clinical and functional status, medication adherence, and limb symptoms at least annually, with reassessment of ischemic and bleeding risk at every follow-up 10.